Chingching Foocharoen,
Alan Tyndall,
Eric Hachulla,
Edoardo Rosato,
Yannick Allanore,
Dominique Farge-Bancel,
Paola Caramaschi,
Paolo Airó,
Starovojtova M Nikolaevna,
José António Pereira da Silva, [......],
Ingo Tarner,
Vanessa Smith,
Anna T Onken,
Walid Ahmed Abdel Atty Mohamed,
Oliver Distler,
Jadranka Morović-Vergles,
Andrea Himsel,
Paloma Garcia de la Peña Lefebvre,
Thomas Hügle,
Ulrich A Walker
[show abstract]
[hide abstract]
ABSTRACT: Erectile dysfunction (ED) is common in men with systemic sclerosis (SSc) but the demographics, risk factors and treatment coverage for ED are not well known.
This study was carried out prospectively in the multinational EULAR Scleroderma Trial and Research database by amending the electronic data-entry system with the International Index of Erectile Function-5 and items related to ED risk factors and treatment. Centres participating in this EULAR Scleroderma Trial and Research substudy were asked to recruit patients consecutively.
Of the 130 men studied, only 23 (17.7%) had a normal International Index of Erectile Function-5 score. Thirty-eight per cent of all participants had severe ED (International Index of Erectile Function-5 score ≤ 7). Men with ED were significantly older than subjects without ED (54.8 years vs. 43.3 years, P < 0.001) and more frequently had simultaneous non-SSc-related risk factors such as alcohol consumption. In 82% of SSc patients, the onset of ED was after the manifestation of the first non-Raynaud's symptom (median delay 4.1 years). ED was associated with severe cutaneous, muscular or renal involvement of SSc, elevated pulmonary pressures and restrictive lung disease. ED was treated in only 27.8% of men. The most common treatment was sildenafil, whose efficacy is not established in ED of SSc patients.
Severe ED is a common and early problem in men with SSc. Physicians should address modifiable risk factors actively. More research into the pathophysiology, longitudinal development, treatment and psychosocial impact of ED is needed.
Arthritis research & therapy 02/2012; 14(1):R37. · 4.27 Impact Factor
